Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) were isolated from varicella-zoster virus-infected Vero cells which were pulse-treated with 5-iododeoxyuridine or 5-bromodeoxyuridine or both and then treated with BV-araU. These BV-araU-resistant strains (BV-araUr) could not be isolated from varicella-zoster virus-infected cells treated with BV-araU alone and had reduced viral thymidine kinase activity. Two of five BV-araUr strains were also resistant to 5-iododeoxyuridine and 5-bromodeoxyuridine, whereas other BV-araUr strains were relatively susceptible to these drugs. All clones from the BV-araUr strain were susceptible to 1-beta-D-arabinofuranosylcytosine and phosphonoacetic acid, but 7 of 10 clones from the BV-araUr strain were resistant to 1-beta-D-arabinofuranosyladenine. The possible mechanisms of induction of BV-araU resistance are discussed.
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000494:pharmacology; D002522:Chlorocebus aethiops; D003001:Cloning, Molecular; D004279:DNA, Viral / Q000096:biosynthesis; D004352:Drug Resistance, Microbial; D004622:Embryo, Mammalian; D005347:Fibroblasts; D006168:Guinea Pigs; D014645:Herpesvirus 3, Human / Q000187:drug effects* / Q000201:enzymology; D007668:Kidney; D013936:Thymidine / Q000378:metabolism; D013937:Thymidine Kinase / Q000378:metabolism; D014529:Uridine / Q000031:analogs & derivatives*; D010948:Viral Plaque Assay; D014776:Virus Cultivation
D000998:Antiviral Agents; D004279:DNA, Viral; D001086:Arabinofuranosyluracil; C031368:sorivudine; D013937:Thymidine Kinase; D013936:Thymidine; D014529:Uridine